Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial
- Kedhi, E.
- Verdoia, M.
- Suryapranata, H.
- Damen, S.A.J.
- Camaro, C.
- Benit, E.
- Barbieri, L.
- Rasoul, S.
- Liew, H.B.
- Polad, J.
- Ahmad, W.A.
- Zambahari, R.
- Lalmand, J.
- Schaaf, R.J. van der
- Koh, T.H.
- Timmermans, P., Sr.
- Dilling-Boer, D.
- Veenstra, L.F.
- van, T.H.A.W.
- Lee, S.W.
- Roolvink, V.
- Ligtenberg, E.
- Postma, S.
- Kolkman, E.J.
- Brouwer, M.A.
- Dudek, D.
- Luca, G. De
DOIAbstract
BACKGROUND AND AIMS: The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy. METHODS: The REDUCE trial is a prospective, multicenter, investigator-initiated study that randomized ACS patients undergoing PCI with the COMBO drug eluting stent to either 3 or 12 months of DAPT. The study population was divided according to age (<or ≥ 75 years). Primary study endp...
Add to ORKG